Phaseline

Companies › Alligator Bioscience

Alligator Bioscience: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
mitazalimab
CD40 agonist
CD40Phase 1Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04888312mitazalimabPhase 1Metastatic Pancreatic Ductal AdenocarcinomaOncologyJun 2026
NCT07199764mitazalimabPhase 2Pancreatic Ductal AdenocarcinomaOncologyOct 2027

Targets

CD40 (1)

Companies with the same targets

AbbVie Xencor Genmab RANI Therapeutics Roche Akamis Bio Veloxis Pharmaceuticals Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.